Ruthenium-106 plaque brachytherapy for the treatment of diffuse choroidal hemangioma in Sturge-Weber syndrome

作     者：Ying-Ying Yu Xiao-Xin Li Jian-Hong Liang 

作者机构：Department of Ophthalmology&Clinical Center of OptometryPeking University People’s HospitalBeijing 100044China Eye Diseases and Optometry Institute Peking University People’s HospitalBeijing 100044China Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid DiseasesBeijing 100044China College of OptometryPeking University Health Science CenterBeijing 100191China 

出 版 物：《International Journal of Ophthalmology(English edition)》 (国际眼科杂志（英文版）)

年 卷 期：2020年第13卷第3期

页      面：513-517页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：diffuse choroidal hemangioma Sturge-Weber syndrome plaque brachytherapy 

摘      要：AIM:To evaluate the efficacy of ruthenium-106 plaque brachytherapy for the treatment of diffuse choroidal hemangioma(DCH)in Sturge-Weber syndrome(SWS).METHODS:A total of 8 patients with DCH in SWS managed with plaque brachytherapy were retrospectively *** were treated with ruthenium-106 plaque therapy(median apex dose:83 Gy)at the thickest tumor *** follow-up,we recorded the tumor thickness,the best-corrected visual acuity(BCVA),subretinal fluid(SRF)status,and complications following ***:At a median follow-up of 43 mo,tumor regression was observed in all cases,with a complete resolution of SRF and reduction in *** radiation complications were recorded during the follow up ***:Ruthenium-106 plaque therapy to the thickest portion of the tumor seems to be a useful treatment in patients with DCH in SWS.